Physician profile
Jack Goldstein
NPI 1114929858
$943.15
in general payments reported to CMS, 2019-2025
19 companies · $73.85 in 2025
The $73.85 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $189 · 2020: $42.09 · 2021: $70.26 · 2022: $234 · 2023: $142 · 2024: $192 · 2025: $73.85.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $407.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $293.36 | 2019-2024 | Xifaxan, Trulance |
| Abbvie INC. | $101.29 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $72.04 | 2019-2024 | Entyvio |
| Janssen Biotech, INC. | $68.45 | 2022-2025 | Tremfya |
| Regeneron Healthcare Solutions, INC. | $48.37 | 2022-2024 | Dupixent |
| Gilead Sciences, INC. | $45.92 | 2022-2025 | |
| Redhill Biopharma INC. | $42.01 | 2021-2023 | |
| Lilly USA, LLC | $38.57 | 2024 | Omvoh |
| Novo Nordisk INC | $37.12 | 2019-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $33.76 | 2023 | Freestyle Libre 3 |
| Ironwood Pharmaceuticals, INC | $30.57 | 2020-2024 | |
| Phathom Pharmaceuticals, INC. | $20.84 | 2025 | Voquezna |
| Xeris Pharmaceuticals, INC. | $19.40 | 2022 | |
| Insulet Corporation | $17.72 | 2023 | Omnipod |
| Ardelyx, INC. | $16.92 | 2024 | Ibsrela |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $15.95 | 2023 | Minimed 780g |
| Celgene Corporation | $15.54 | 2024 | Zeposia |
| Organon LLC | $13.63 | 2022 | |
| Shionogi INC | $11.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Goldstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.